Presentation is loading. Please wait.

Presentation is loading. Please wait.

Absolute risk reductions or increases of overall discontinuation or discontinuation because of adverse events comparing non-pharmacological interventions.

Published byMarcus Ola Ervik Modified over 5 years ago

Similar presentations

Presentation on theme: "Absolute risk reductions or increases of overall discontinuation or discontinuation because of adverse events comparing non-pharmacological interventions."— Presentation transcript:

1 Absolute risk reductions or increases of overall discontinuation or discontinuation because of adverse events comparing non-pharmacological interventions with inactive interventions. CBT, cognitive behavioural therapy; SAMe, S-adenosyl-L-methionine; SGA, second-generation antidepressants; TCA, tricyclic antidepressants. Absolute risk reductions or increases of overall discontinuation or discontinuation because of adverse events comparing non-pharmacological interventions with inactive interventions. CBT, cognitive behavioural therapy; SAMe, S-adenosyl-L-methionine; SGA, second-generation antidepressants; TCA, tricyclic antidepressants. Gerald Gartlehner et al. BMJ Open 2017;7:e014912 ©2017 by British Medical Journal Publishing Group

Download ppt "Absolute risk reductions or increases of overall discontinuation or discontinuation because of adverse events comparing non-pharmacological interventions."

Similar presentations

Characteristics of studies on lifestyle interventions included in review Gillies CL, et al. BMJ 2007;334:299-307.

Characteristics of studies on lifestyle interventions included in review Gillies CL, et al. BMJ 2007;334:
From: Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients With Major Depressive Disorder: A Clinical Practice Guideline From the American.

From: Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients With Major Depressive Disorder: A Clinical Practice Guideline From the American.
The NAS2 audit requested whether CBTp was ‘taken up’, and we examined this in two ways: service users with at least one session of CBTp, which is represented.

The NAS2 audit requested whether CBTp was ‘taken up’, and we examined this in two ways: service users with at least one session of CBTp, which is represented.
Number of local authorities (LAs) commissioning each service directly or indirectly (n=148) (*Flu vaccination data excludes the service commissioned across.

Number of local authorities (LAs) commissioning each service directly or indirectly (n=148) (*Flu vaccination data excludes the service commissioned across.
Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)
Mean expense per year on courses and conferences that trainees have not been reimbursed. Mean expense per year on courses and conferences that trainees.

Mean expense per year on courses and conferences that trainees have not been reimbursed. Mean expense per year on courses and conferences that trainees.
Daily contribution (%) of sodium and potassium from major food groups among participants aged 8–12 years (n=517), which includes major food groups provided.

Daily contribution (%) of sodium and potassium from major food groups among participants aged 8–12 years (n=517), which includes major food groups provided.
Defining study follow-up periods—index date (entry into cohort) and breaks in MSP registration. †End of follow-up due to earliest of: active TB diagnosis,

Defining study follow-up periods—index date (entry into cohort) and breaks in MSP registration. †End of follow-up due to earliest of: active TB diagnosis,
Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in.

Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in.
Scatter graph showing total work time equivalent of all specialist palliative care practitioners commissioned by the Clinical Commissioning Group (CCG)

Scatter graph showing total work time equivalent of all specialist palliative care practitioners commissioned by the Clinical Commissioning Group (CCG)
Scatter graph showing the total number of specialist palliative care beds commissioned compared with the estimated number of people with palliative care.

Scatter graph showing the total number of specialist palliative care beds commissioned compared with the estimated number of people with palliative care.
Estimated probability of successful quitting (quit attempt of longer than 1 year) by quit attempt number in the Ontario Tobacco Survey. Estimated probability.

Estimated probability of successful quitting (quit attempt of longer than 1 year) by quit attempt number in the Ontario Tobacco Survey. Estimated probability.
Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and 2012. Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and.

Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and.
A schematic representation of the possible pairwise comparisons of adherence and persistence between different medication classes. A schematic representation.

A schematic representation of the possible pairwise comparisons of adherence and persistence between different medication classes. A schematic representation.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.
1-year and 5-year survival rates by cancer type, stage and group, England, up to 2011–2015. 1-year and 5-year survival rates by cancer type, stage and.

1-year and 5-year survival rates by cancer type, stage and group, England, up to 2011– year and 5-year survival rates by cancer type, stage and.
Risk of having any adverse effects with supplements compared with placebo. Risk of having any adverse effects with supplements compared with placebo. Stratified.

Risk of having any adverse effects with supplements compared with placebo. Risk of having any adverse effects with supplements compared with placebo. Stratified.
Flow diagram of sample selection and reduction of subject numbers by application of exclusion criteria. ‡Data from Medical Record; ‡‡Records missing gender.

Flow diagram of sample selection and reduction of subject numbers by application of exclusion criteria. ‡Data from Medical Record; ‡‡Records missing gender.
Suggested implementation approach for the prevention of oral mucositis guideline recommendations (HSCT, haematopoietic stem cell transplantation; KGF,

Suggested implementation approach for the prevention of oral mucositis guideline recommendations (HSCT, haematopoietic stem cell transplantation; KGF,

Similar presentations

Ads by Google